VTE Treatment & Anticoagulation Management
Last Update 1st September 2026
VTE Treatment & Anticoagulation Management
Ongoing management of a patient on an oral anticoagulant. For acute diagnosis and initial treatment of a clot see Pulmonary Embolism and DVT — Investigation; for stroke prevention in AF see Atrial Fibrillation.
Choosing an agent
DOACs are preferred over vitamin K antagonists for the two commonest long-term indications — stroke prevention in atrial fibrillation, and venous thromboembolism. The exceptions:
- Mechanical heart valves, and moderate-to-severe mitral stenosis — warfarin.
- Antiphospholipid syndrome — warfarin. A meta-analysis of randomised trials showed a significantly higher risk of arterial thrombotic events with DOACs than with vitamin K antagonists, driven mainly by stroke.
- Pregnancy and breastfeeding — LMWH.
- Severe renal impairment — warfarin or LMWH. Apixaban is contraindicated below CrCl 25 mL/min, rivaroxaban below 15 mL/min.
- Morbid obesity — warfarin is often preferred.
- Adherence is the problem — warfarin may be safer. A DOAC’s short half-life means missing even a single dose could result in a period of minimal anticoagulation, and there is no INR to reveal that it happened.
A patient with adequate renal and hepatic function, not taking interacting drugs, who wishes to minimise blood tests, is a good candidate for a DOAC.
DOAC pharmacokinetics are less predictable than often claimed. For a given dose of dabigatran, the 10th to 90th centiles of steady-state concentrations spanned a five-fold range. What is established is non-inferiority to INR-targeted warfarin, not consistent plasma levels.
Duration for VTE
All proximal DVT and PE should receive anticoagulant therapy for at least 3 months. Those provoked by major surgery or major trauma can cease at that point.
Distal DVT is less certain. Anticoagulation is generally used as for proximal DVT, though serial ultrasound — two scans over two weeks — is reasonable, particularly where bleeding risk is raised. Most distal DVT can be treated for 6–12 weeks.
Beyond 3–6 months, the decision turns on recurrence risk against bleeding risk, and clinical equipoise is common — patient preference matters. The predictors worth weighing:
- Unprovoked, or provoked by a non-surgical transient or persistent risk factor, versus provoked by surgery
- PE and proximal DVT versus distal DVT
- Prior VTE
- Male sex
Extended anticoagulation should be considered for unprovoked PE or proximal DVT, or one provoked by a non-surgical transient or persistent risk factor, especially in males.
Continuing beyond 3 months reduces recurrence during therapy by at least 80%, at the cost of under 1% per year of extra bleeding. It does not change what happens after stopping — once anticoagulation stops, recurrence risk is the same as in someone who stopped at 3–6 months. Extended therapy defers risk; it does not cure it.
Low-intensity extended anticoagulation
If extending beyond 6 months, consider dropping the dose:
- Apixaban 2.5 mg twice daily is as efficacious as 5 mg twice daily for preventing recurrence beyond 6 months, with no difference in major bleeding.
- Rivaroxaban 10 mg once daily is as efficacious as 20 mg once daily, with a trend to less major and clinically relevant non-major bleeding.
Aspirin is not a substitute. It reduces recurrence far less than an oral anticoagulant for similar bleeding rates — rivaroxaban 10 mg reduced recurrence by 74% relative to aspirin, with a major bleeding rate of 0.3%. Aspirin should be avoided unless anticoagulation cannot be used at all.
Monitoring
Renal function should be checked at least annually, and more often with changing circumstances such as a diuretic change in heart failure — 6–12 monthly is a reasonable default on a DOAC, since renal impairment increases bleeding risk with all of them.
Use creatinine clearance (Cockcroft-Gault), not eGFR. All the oral anticoagulant trials used CrCl in mL/min; an eGFR reported in mL/min/1.73 m² should be adjusted for body surface area, especially at the extremes of size.
At each review, check adherence, symptoms and signs of bleeding, new or changed comorbidities, and concomitant medicines.
Routine coagulation testing does not guide DOAC dosing. INR, aPTT and thrombin time all correlate loosely with DOAC concentration, but the relationship varies by drug and by laboratory — interpret only with local specialist input. Coagulation testing is for an acute thrombotic or bleeding event, not for ambulatory dose adjustment.
Interactions
Clinically important DOAC interactions run mainly through P-glycoprotein and CYP3A4, plus additive haemostatic impairment from other antithrombotics. Apixaban and rivaroxaban are CYP3A4 and P-gp substrates; dabigatran is P-gp only; warfarin is CYP2C9.
- Increase anticoagulant effect — erythromycin and clarithromycin, ketoconazole, ritonavir, verapamil (dabigatran), amiodarone (warfarin)
- Decrease it — rifampicin, St John’s wort
Ask about over-the-counter NSAIDs and herbal supplements specifically; patients rarely volunteer them.
Interruption for a procedure
The PAUSE study supported simple interruption without heparin bridging or routine drug-level testing. Routine preoperative DOAC level measurement is not recommended for elective procedures.
- Low-to-moderate bleeding-risk procedure — hold 1 day before
- High bleeding-risk procedure — hold 2 days before
- Neuraxial procedures — more than 3 days for factor Xa inhibitors, more than 4 days for dabigatran, because of spinal haematoma risk
- Longer interruption in renal impairment, particularly for dabigatran
Heparin bridging is not recommended — DOACs have short half-lives and rapid onset, and bridging increases bleeding without reducing thrombotic risk.
Restart 24 hours after a low-risk procedure and 48–72 hours after a high-risk one, once haemostasis is achieved. Prophylactic-dose LMWH can cover a high-thrombotic-risk patient whose DOAC restart is delayed.
Bleeding
For minor bleeding such as mild epistaxis, local measures may be adequate. For serious bleeding, stop the anticoagulant at least until bleeding is stabilised and the patient’s ongoing bleeding risk has been evaluated. Severe bleeding goes to hospital.
Reversal is a hospital decision and is reserved for life-threatening, uncontrolled, or critical-site bleeding, or when an urgent procedure is required — reversal itself carries thromboembolic risk. What they will do:
- Warfarin — 4-factor prothrombin complex concentrate 50 U/kg IV plus IV vitamin K 5–10 mg. Fresh frozen plasma is a less effective alternative.
- Dabigatran — idarucizumab 5 g IV as two 2.5 g boluses. Haemodialysis removes roughly 60% of the drug in 2–3 hours.
- Factor Xa inhibitors — 4-factor prothrombin complex concentrate 50 U/kg IV. Andexanet alfa availability varies by jurisdiction; check locally rather than assuming.
Outside those settings, the main antidote is time. Concentrations and anticoagulant effect fall by more than 90% after four half-lives — in a patient with normal renal and hepatic function, more than 90% within 48 hours of stopping.
Restarting after a major bleed
Resumption is usually of net clinical benefit once the source is controlled. Guidelines suggest restarting between 2 weeks and 90 days, individualised on thrombotic versus bleeding risk, earlier where thrombotic risk is high.
- After gastrointestinal bleeding — resumption within 7 days reduces thromboembolism and mortality, at the cost of a modest increase in rebleeding.
- After intracranial haemorrhage — more cautious: typically 4–8 weeks, or longer where rebleeding risk is high, as in cerebral amyloid angiopathy.
Apparent treatment failure
True anticoagulant failure is uncommon — around 2% of treated patients, at similar rates for DOACs and warfarin. Before labelling it, confirm true recurrence objectively, in a previously unaffected vascular territory, and exclude residual thrombosis or an alternative diagnosis.
If recurrence is confirmed on therapeutic anticoagulation, switch to a parenteral agent such as LMWH rather than swapping one DOAC for another, and involve a specialist — particularly with cancer, antiphospholipid syndrome, or significant renal or gastrointestinal impairment.
Patient education
Structured and repeated, not a one-off. Cover:
- The indication, and strict adherence — including what to do after a missed dose
- Warning signs needing urgent care: melaena, haematemesis, haematuria, new severe headache, focal neurological deficit
- Telling any clinician about the anticoagulant before a procedure or a new prescription